BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237 [PMID: 24363513 DOI: 10.3748/wjg.v19.i45.8227]
URL: https://www.wjgnet.com/1007-9327/full/v19/i45/8227.htm
Number Citing Articles
1
A. Rousseau, M. Labetoulle. Effets indésirables oculaires des traitements systémiques : une mise à jourJournal Français d'Ophtalmologie 2015; 38(9): 876 doi: 10.1016/j.jfo.2015.05.004
2
Zubir S. Rentiya, Matthew Wells, Junun Bae, Kuan-Jen Chen, An-Ning Chao, Nicholas Turgeon, Syed M. Shah, Mostafa Hanout. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendationsGraefe's Archive for Clinical and Experimental Ophthalmology 2019; 257(3): 447 doi: 10.1007/s00417-018-04209-7
3
Walid Sharif, Khayam Sheikh, Ian De Silva, Samer Elsherbiny. Nonarteritic anterior ischemic optic neuropathy associated with interferon and ribavirin in a patient with hepatitis CAmerican Journal of Ophthalmology Case Reports 2017; 5: 52 doi: 10.1016/j.ajoc.2016.12.004
4
Peng-Tai Tien, Chun-Ju Lin, Yi-Yu Tsai, Huan-Sheng Chen, De-Kuang Hwang, Chih-Hsin Muo, Jane-Ming Lin, Wen-Lu Chen. RELATIONSHIP BETWEEN UVEITIS, DIFFERENT TYPES OF VIRAL HEPATITIS, AND LIVER CIRRHOSISRetina 2016; 36(12): 2391 doi: 10.1097/IAE.0000000000001103
5
Faizah Ilyas, Harmanjit Singh, Navin Anand, Iqbal Ike K. Ahmed. Intraocular pressure rise in the course of peginterferon alpha-2a, ribavirin, and boceprevir therapy for hepatitis CCanadian Journal of Ophthalmology 2015; 50(6): e112 doi: 10.1016/j.jcjo.2015.08.013